IQVIA Launches Digital ICF Author, a SaaS eConsent Tool to Transform the Informed Consent Process

IQVIA™ (NYSE:IQV) announced today the launch of Informed Consent Form (ICF) Author, a SaaS eConsent tool for use in clinical trials. The online portal allows sponsors, sites, and contract research organizations (CROs) to produce their own ICFs for delivery via eConsent or traditional paper.

IQVIA Technologies’ ICF Author makes it easier to manage and track the authorship, review, and approval processes using configurable workflows, checklists, and automated version control. This dramatically improves the visibility and transparency of the process and leads to improved compliance.

"This product opens up the realm of eConsent to anyone and everyone,” said Tal Rosenberg, senior vice president, Global Technology Solutions at IQVIA. "Sponsors and CROs who want to manage their own processes are now able to do so, with a system that’s easy and intuitive.”

The user-friendly ICF Author is completely digital and can be used with both online and offline consent protocols. The tool gives users the ability to automate creation, distribution, tracking, and monitoring of informed consent forms, while simplifying the experience for everyone involved, including patients.

Features and benefits of ICF Author include

• Providing study teams with the tools, training, and best-practice resources they need to create, manage, and automate consent solutions in-house.
• Streamlining the time and cost of development and implementation.
• Reducing some of the most common audit issues regarding good clinical practices.
• Implementing automatic scalability to as few or as many studies as needed while providing complete control.

ICF Author reinforces IQVIA Technologies’ commitment to providing solutions that transform clinical research through collaboration, standardization, and a seamless technology experience.

Additional information about ICF Author SaaS eConsent is available at https://www.drugdev.com/iqvia-icf-author/.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation, and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology, and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps its customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Click here to subscribe to Mobile Alerts for IQVIA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005246/en/